Mereo BioPharma Group plc (MREO) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
MREO currently has 802M outstanding shares. with limited dilution risk as only 102M additional shares (12.8%) are authorized for issuance. The company has diluted shareholders by 24.96% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 12, 2026 |
10-Q filing | 801.8M shares outstanding |
800M | 100M |
| Mar 19, 2026 |
10-K filing | 797.1M shares outstanding |
800M | 100M |
| Aug 12, 2025 |
10-Q filing | 799.4M shares outstanding |
800M | 100M |
| May 13, 2025 |
10-Q filing | 784.3M shares outstanding |
780M | 100M |
| Mar 26, 2025 |
10-K filing | 739.6M shares outstanding |
740M | 100M |
| Nov 25, 2024 |
S-3 filing: Mereo BioPharma Group plc is offering 26,638,972 ordinary shares in the form of American Depositary Shares by selling shareholders. |
770M | 100M |
| Nov 12, 2024 |
8-K filing: Mereo BioPharma Group plc entered into an amendment agreement with AstraZeneca, agreeing to issue 2,044,392 ordinary shares and pay $0.5 million to AstraZeneca in connection with an agreed milestone. |
710M | 76M |
| Nov 12, 2024 |
10-Q filing | 770.1M shares outstanding |
770M | 76M |
| Aug 13, 2024 |
10-Q filing | 711.8M shares outstanding |
710M | 76M |
| May 15, 2024 |
S-3 filing: Mereo BioPharma Group plc proposes to offer and sell American Depositary Shares for an aggregate offering price of up to $175,000,000 in one or more offerings, including an at-the-market offering of up to $50,000,000 through Jefferies. |
660M | 76M |
| May 15, 2024 |
10-Q filing | 700.3M shares outstanding |
700M | 76M |
| Mar 27, 2024 |
10-K filing | 659.5M shares outstanding |
660M | 0 |
| Mar 28, 2023 |
20-F filing | 624.9M shares outstanding |
620M | 0 |
| Mar 31, 2022 |
20-F filing | 584.9M shares outstanding |
580M | 0 |
| Aug 05, 2021 |
F-3 filing: This is an at-the-market offering of ADSs having an aggregate offering price of up to $50,000,000 through Jefferies LLC. The company intends to use the net proceeds from this offering for general corporate purposes. |
340M | 0 |
| Mar 31, 2021 |
20-F filing | 339.0M shares outstanding |
340M | 0 |
| Oct 06, 2020 |
F-3 filing: This F-3 filing is a supplement to the base prospectus for an at-the-market offering of American Depositary Shares (ADSs) with an aggregate offering price of up to $50,000,000 through sales agent SVB Leerink LLC, intended for general corporate purposes. |
340M | 0 |
| Jul 06, 2020 |
F-3 filing: This is an F-3 filing for Mereo BioPharma Group plc related to the offering of ordinary shares underlying the ADSs. Expenses related to the offering are estimated to be $195,146.69. |
340M | 0 |
| Jul 02, 2020 |
POS AM filing: This POS AM filing registers ADSs offered by the selling shareholder, including shares issuable to Aspire Capital under a Purchase Agreement. |
340M | 0 |
| Jun 15, 2020 |
20-F filing | 98.0M shares outstanding |
98M | 0 |
| Feb 18, 2020 |
F-1 filing: This is an F-1 filing related to an offering of securities, with details provided on estimated expenses and legal matters. |
N/A | 0 |